A prospective study reported that rising circulating Granzyme B and activated cytotoxic lymphocytes tracked response and survival in patients receiving second-line nivolumab for advanced NSCLC. Investigators used longitudinal sampling to follow immune activation markers alongside clinical outcomes, finding that immune dynamics improved risk discrimination beyond static baseline measures. The work supports continued development of peripheral biomarkers to monitor checkpoint therapy efficacy in real time rather than relying only on imaging intervals.
Get the Daily Brief